Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bausch & Lomb and Galapagos to collaborate on ophthalmic disease research
May 2008
SHARING OPTIONS:

ROCHESTER, N.Y.—Eye health company Bausch & Lomb and genomics-based drug discovery company Galapagos NV announced last month they will collaborate on ophthalmic disease research. Under the agreement, Bausch & Lomb will have the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.

Galapagos will receive an upfront payment of $400,000 and may receive research funding to support Bausch & Lomb's further development of the compounds for ophthalmic uses, plus future milestone payments. Pending successful development and commercialization under the license, potential total value of the payments exceeds $50 million. Galapagos is headquartered in Mechelen, Belgium. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.